| Document |
Document Title |
|
WO/2022/167962A1 |
The present invention is directed to compound of formula (I) and, a pharmaceutically acceptable salt or a stereoisomer thereof that useful as MALT-1 inhibitors for the treatment of diseases or disorders dependent on MALT-1. The present i...
|
|
WO/2022/167866A1 |
The present disclosure relates in part to chemical modulators of protein phosphatase 2A (PP2A), comprising formula (I). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, aut...
|
|
WO/2022/166990A1 |
Provided in the present invention are a 2-(substituted phenoxy)aromatic formic acid FTO inhibitor, a preparation method therefor and the use thereof, and specifically disclosed are a compound represented by formula (I), and the use of a ...
|
|
WO/2022/162447A1 |
The present invention generally relates to a process for preparation of chlorantraniliprole or a salt thereof. Further, the present invention relates to an improved process for preparation of intermediate of chlorantraniliprole.
|
|
WO/2022/164239A1 |
A novel pyrazole-carboxamide derivative compound provided as one example of the present invention exhibits an antagonist activity specific to cannabinoid receptor 1, and thus has a technical effect of effectively preventing or treating d...
|
|
WO/2022/164857A1 |
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N -oxides, and salts thereof, Wherein R1, R2, R3, A, X and Q are as defined in the disclosure. Also disclosed are compositions containing the compounds of F...
|
|
WO/2022/165162A1 |
Selective inhibitors of cyclin-dependent kinases (CDKs) and methods of their therapeutic use, including treatment of viral infections, are disclosed.
|
|
WO/2022/161418A1 |
The present invention relates to a compound of chemical formula (I), a preparation method therefor, and an application thereof, as well as a pharmaceutical composition comprising the compound as an active ingredient, or a pharmaceuticall...
|
|
WO/2022/159454A1 |
In one aspect, the present disclosure provides compounds which inhibit bromodomain testis (BRDT). In some embodiments, the compounds inhibit bromodomain-2 of BRDT. In another aspect, the present disclosure provides a method of inhibiting...
|
|
WO/2022/159445A1 |
The present disclosure is generally directed to activators of lipoprotein lipase useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I), or a pharmaceutically acceptable salt, isomer, solvat...
|
|
WO/2022/159532A1 |
This disclosure relates to a molecule, N-(3-chloro-1H-pyrazol-4-yl)-2- (methylsulfonyl)propanamide (S2b) and processes to prepare S2b and N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-2- (methylsulfonyl)propanamide (S3b) having pesticida...
|
|
WO/2022/155471A1 |
The present disclosure relates to the finding that certain compounds that modulate the activity(ies) of Sigma receptors can be used to treating or ameliorate nonalcoholic fatty liver disease and related diseases or disorders. In certain ...
|
|
WO/2022/147993A1 |
Provided are a diphenylpyrazole compound as represented by formula (I) below or an agrochemically acceptable salt thereof, which is a novel inhibitor targeting pest GSTs, has a wide range of inhibitory activity on GSTs in various pests, ...
|
|
WO/2022/149617A1 |
The present invention provides a library which comprises from 1 × 102 to 1 × 108 compounds; the compounds have a structure in which a first core block (first CB), a first linker (first L) and a second core block (second CB) are covalen...
|
|
WO/2022/147318A1 |
Provided are methods for the parenteral use of 3-methoxy-N-[3-(2-methylpyrazol-3-yl)-4-(2-morpholin-4-yleth
oxy)phenyl]benzamide, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and the sequential use of parenteral an...
|
|
WO/2022/144926A1 |
The present invention relates to amorphous form of N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan
-2-yl}-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide of formula-1, having specific surface area (SSA) in the range from about ...
|
|
WO/2022/147302A1 |
The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
|
|
WO/2022/134287A1 |
The present invention relates to a method for preparing a carboxylic acid ester compound. Under the catalysis of nitrite, an carboxylic acid reacts with an alcohol in air so as to obtain an ester compound; and the alcohol is ethanol, pro...
|
|
WO/2022/140520A1 |
Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compo...
|
|
WO/2022/138944A1 |
The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the f...
|
|
WO/2022/135442A1 |
The present invention provides a CDK2 inhibitor and a preparation method therefor. Specifically, the present invention provides a compound as represented by formula I or a pharmaceutically acceptable salt and tautomer thereof. Groups are...
|
|
WO/2022/135365A1 |
Provided herein are novel compounds (e.g., Formula I or II), pharmaceutical compositions, and methods of using related to cyclin dependent kinases (CDKs). The compounds herein are typically CDK2 inhibitors, which can be used for treating...
|
|
WO/2022/134297A1 |
The present invention relates to a preparation method for a carboxylate ester compound, comprising: under the catalysis of a nitrite ester, reacting carboxylic acid and methanol in air, so as to obtain an ester compound. The preparation ...
|
|
WO/2022/132803A1 |
Provided herein are compounds, compositions, and methods for treating disorders (e.g., opioid addiction) using compounds disclosed herein, which are selective agonists of the cannabinoid 2 receptor (CB2R).
|
|
WO/2022/129047A2 |
The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorder...
|
|
WO/2022/129041A1 |
The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurologi...
|
|
WO/2022/131146A1 |
Provided is a compound having the effect of inhibiting HIF-1. In concrete terms, the present invention provides a specific nitrogen-containing heterocyclic compound.
|
|
WO/2022/129908A1 |
The present invention relates to a cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof. The cannabinoid derivative of the invention is an analogue of cannabidiol (CBD). CBD is a non-psychoactive...
|
|
WO/2022/129909A1 |
The present invention relates to a group of novel compounds, methods for their manufacture and the use of these compounds as research tools and as pharmaceuticals. The novel compounds are analogues of cannabidiol (CBD). CBD is a non-psyc...
|
|
WO/2022/023496A9 |
The present invention relates to functionalized isonitrile compounds, formed by means of multicomponent environmentally friendly reactions, suitable for coupling to functional molecules such as biomolecules, APIs, chromophore and fluorop...
|
|
WO/2022/122773A1 |
The present invention relates to 4-(2-Fluoro-4-methoxy-5-3-(((l- methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)
carbamoyl)phenoxy)-l-methylcyclohexane-l-carboxylic acid derivatives and similar compounds of formula (I) as R...
|
|
WO/2022/125636A1 |
Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compo...
|
|
WO/2022/056346A9 |
Oral dosage forms comprising eltrombopag choline, processes for preparation thereof and methods of use thereof are disclosed. The compositions disclosed exhibit enhanced bioavailability and reduced food effect compared to commercially av...
|
|
WO/2022/118959A1 |
The problem addressed by the present invention is to provide a compound used in the formation of an optically anisotropic film that excels in a reverse wavelength dispersion property and a heat-and-moisture durability property, a polymer...
|
|
WO/2022/118951A1 |
The present invention addresses the problem of providing: a compound to be used in forming an optically anisotropic film having excellent reverse wavelength dispersion properties; a polymerizable composition; an optically anisotropic fil...
|
|
WO/2022/111493A1 |
A use of a complex of an ARB metabolite and an NEP inhibitor in the preparation of drugs for the prevention and/or treatment of nephropathy.
|
|
WO/2022/111605A1 |
The present disclosure relates to an aryl or heteroaryl substituted 5-membered aromatic heterocyclic compound and the use thereof. In particular, provided is a compound as shown in formula I or a pharmaceutically acceptable salt thereof,...
|
|
WO/2022/111694A1 |
The present invention relates to a quinazolinone compound, a preparation method therefor and an application thereof. The compound has a structure represented by formula (I) or formula (LI), has an excellent HPPD inhibitory effect and a s...
|
|
WO/2022/108261A1 |
The present invention provides a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, and a composition for forming an organic layer.
|
|
WO/2022/106596A1 |
The invention relates to a composition comprising (i) a specific pyrazole or an agriculturally acceptable salt thereof; (ii) a phosphonic acid or an agriculturally acceptable salt thereof; (iii) optionally, one or more carboxylic acids, ...
|
|
WO/2022/100614A1 |
Disclosed are a benzourea ring derivative as represented by formula (I) or a pharmaceutically acceptable salt thereof, and a preparation method therefor and the use thereof.
|
|
WO/2022/099374A1 |
The present invention relates to a compound of formula (I): or a salt or solvate thereof, combinations comprising same, uses and methods thereof, and kits comprising same.
|
|
WO/2022/100625A1 |
The present invention relates to novel compounds effectively antagonizing LPAR, which are a compound as shown in formula (I), or a stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug of the compound as shown in fo...
|
|
WO/2022/096679A1 |
The present invention relates to compounds that modulate the conformation of Aurora Kinase A (AURKA). The compounds of the present invention are also modulators of the interactome of AURKA, and preferably alter the protein-protein intera...
|
|
WO/2022/096450A1 |
The present invention relates to the use of [(1,5-diphenyl-1H-pyrazol-3-yl)oxy] acetic acid derivatives of the formula (I) and their salts (I) and compositions containing them, for reducing phytotoxic effects of agrochemicals, in particu...
|
|
WO/2022/094244A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (I SR) and for treating related diseases, disorders, and conditions.
|
|
WO/2022/090071A1 |
The present invention relates to the use of mefenpyr-diethyl for controlling phytopathogenic fungi. Further the invention relates to methods for controlling phytopathogenic fungi, wherein the fungi, their habitat, their locus, or the pla...
|
|
WO/2022/090069A1 |
The present invention relates to compositions comprising mefenpyr-diethyl and a compound selected from mefentrifluconazole, metyltetraprole, benzovindiflupyr, pydiflumetofen, inpyrflux-am, isoflucypram, cyclobutrifluram, fluindapyr, pyra...
|
|
WO/2022/089604A1 |
Provided are crystalline forms of a KRAS G12C inhibitor compound and to processes for their preparation. Furthermore, provided is pharmaceutical composition comprising said crystalline forms, and at least one pharmaceutically acceptable ...
|
|
WO/2022/092310A1 |
The present invention provides a compound, etc. which has aldehyde dehydrogenase 2 (ALDH2) activating activity. Provided are a compound represented by formula (1), a pharmaceutically acceptable salt thereof, and a prodrug thereof. [In th...
|
